BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor

Hui-Jen Tsai¹,²,³ | Weir-Torn Jiaang⁴ | Neng-Yao Shih¹ | Jonathan A. Fletcher⁵ |
Ming-Jon Lin¹ | Ming-Yu Yang⁶,⁷ | Chiung-Tong Chen⁴ | Tsu-An John Hsu⁴ |
Chun-Chieh Wu⁸ | Hui-You Lin¹ | Li-Tzung Chen¹,²,⁹,¹⁰

¹National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
²Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan
³Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
⁴Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan
⁵Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
⁶Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
⁷Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
⁸Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
⁹Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
¹⁰Institute of Molecular Medicine, National Cheng Kung University, Tainan, Taiwan

Correspondence
Hui-Jen Tsai, National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Email: hjtsai@nhri.org.tw

Funding information
National Health Research Institutes, Grant/Award Number: CA104-PP-18, CA-105-PP-18: Ministry of Science Technology, Grant/Award Number: 104-2325-B-400-003, 105-2325-B-400-002, 103-2314-B-400-013

Gastrointestinal stromal tumor (GIST) is a type of KIT-driven cancer. KIT gene mutations are found in approximately 80% of GISTs, and most of these mutations occur in exon 9 and exon 11. Imatinib has been successfully used as a first-line treatment for advanced GIST, with a significant improvement in progression-free survival (PFS) and overall survival. However, disease progression might develop due to primary or secondary resistance to imatinib. Sunitinib and regorafenib have been approved as second- and third-line treatments for advanced GIST patients, with median PFS values of 6.8 and 4.8 months, respectively. However, these relatively modest improvements in PFS underscore the need for more effective KIT inhibitors. BPR1J373 is a multitargeted kinase inhibitor that has been shown to inhibit the proliferation of KIT-driven acute myeloid leukemia cells in vitro and in vivo. In this study, we found that BPR1J373 inhibited proliferation and induced apoptosis by targeting KIT in GIST cells with KIT gene mutations. BPR1J373 also induced cell cycle arrest and senescent change in KIT-mutant GIST48 cells, probably by targeting aurora kinase A. In the KIT-null COS-1 cell-based system, BPR1J373 effectively inhibited KIT with single or double mutations of KIT developed in GIST. The antiproliferative effect was also consistently evident in GIST430 tumor-grafted mice. The results suggest that BPR1J373 could be a potential anticancer drug for GIST and deserves further investigation for clinical applications.
INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are neoplasms arising from mesenchymal tissue of the gastrointestinal tract and are thought to originate from progenitors of the interstitial cells of Cajal. The stomach and small intestine are the most common sites of GISTs, and approximately 60% of GISTs can be cured by surgery. However, approximately 40% of patients initially diagnosed with localized GISTs develop metastasis.\(^1\) Gastrointestinal stromal tumors are a type of KIT-driven cancer, which was found by Hirota et al\(^2\) in 1998 to harbor mutations in the KIT oncogene. Gastrointestinal stromal tumors are usually unresponsive to conventional chemotherapy. Imitinib, which targets platelet-derived growth factor receptor (PDGFR) and Bcr-Abl,\(^3,4\) was shown to induce a good response in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients in phase I/II studies and was approved as a first-line treatment for both diseases.\(^5-8\) In 2000, Heinrich et al\(^9\) showed that this drug could inhibit the phosphorylation of KIT in KIT-mutated HMC-1 cells and effectively inhibit the proliferation of HMC-1 cells. Imitatinib was also shown to induce a notably good response in an advanced GIST patient who had failed multiple treatments.\(^10\) In addition, imatinib treatment achieved a disease control rate of 81.6% for advanced GIST, leading to significant improvement in progression-free survival (PFS) and overall survival (OS) in the initial phase II study.\(^11\) Therefore, imatinib has become the first-line treatment for advanced GIST with a long-term median OS of 51-57 months in phase II and phase III trials.\(^12,13\)

Disease progression of GIST might develop further due to either primary or secondary resistance to imatinib.\(^14,15\) KIT mutations are found in approximately 80% of GISTs, and mutations in exons 9 and 11 are the most frequent at diagnosis.\(^16,17\) Patients with exon 9 mutations have a lower response rate to imatinib and inferior PFS and OS when compared with patients with primary exon 11 mutations.\(^16-20\) Secondary mutations of KIT occur in exons 13, 14, 17, or 18, which might indicate a clonal selection after multiple treatments.\(^10\) In addition, imatinib treatment achieved a disease control rate of 81.6% for advanced GIST, leading to significant improvement in progression-free survival (PFS) and overall survival (OS) in the initial phase II study.\(^11\) Therefore, imatinib has become the first-line treatment for advanced GIST with a long-term median OS of 51-57 months in phase II and phase III trials.\(^12,13\)

In 2013 as the third-line treatment for GIST patients who failed to respond, or were intolerant to, treatment with imatinib and sunitinib, according to results from a phase III study.\(^25\) The median PFS was 4.8 months compared with 0.9 month for the placebo control group. Therefore, for refractory GIST, development and identification of novel agents are mandatory.

BPR1J373, a 5-phenylthiazol-2-ylamine-pyrimidine derivative, is a multitargeted kinase inhibitor with potent inhibitory activity against fms like tyrosine kinase 3, KIT, vascular endothelial growth factor receptor (VEGFR), Aurora A, Aurora B, PDGFR\(\alpha\), PDGFR\(\beta\), rearranged during transfection, and sarcoma in preliminary kinase profiling. The structure of BPR1J373 was shown previously.\(^26\) The antikinase profile of BPR1J373 is presented in Figure S1. BPR1J373 has been shown to inhibit proliferation of KIT-driven acute myeloid leukemia cells in vitro and in vivo.\(^26\) In this study, we report the effectiveness and mechanisms by which BPR1J373 inhibits the proliferation of KIT-mutant GIST cells in vitro and in vivo.

MATERIALS AND METHODS

2.1 Cell lines and reagents

The GIST cell lines GIST882, GIST48, GIST430, GIST-T1, GIST62, GIST48B, and COS-1 were selected for the current study. All cells were cultured in incubators maintained at 37°C and 5% CO\(_2\). GIST882 and GIST62 were cultured in RPMI-1640 supplemented with 20% FBS. GIST-T1 was cultured in RPMI-1640 supplemented with 10% FBS. GIST48 and GIST48B were cultured in F10 supplemented with 20% FBS. GIST48 and GIST48B were cultured in F10 supplemented with 20% FBS, 0.5% Mito ± serum extender (355006; BD Biosciences, San Jose, CA, USA) and 1% pituitary extract bovine (354123; BD Biosciences). GIST430 was cultured in Iscove’s modified Dulbecco’s medium supplemented with 20% FBS. COS-1 was cultured in DMEM supplemented with 10% FBS. GIST882, GIST430, GIST48, GIST48B, and GIST48B cells were gifts from Dr. Jonathan A. Fletcher (Harvard Medical School, Boston, MA, USA) in 2010. COS-1 cells were obtained from Dr. Neng-Yao Shih (National Health Research Institutes [NHRI]) (Tainan, Taiwan) in 2013. GIST-T1 cells were obtained from Dr. Yan-Shen Shan (National Cheng Kung University Hospital, Tainan, Taiwan) in 2018. Because no database is available for checking cell line authentication, we used direct sequencing in December 2016 for GIST882, GIST430, and GIST48 cells and confirmed that a homozygous mutation of K642E exists for GIST882, an exon 11 in-frame deletion and a heterozygous secondary exon 13 missense mutation (V654A) exist for GIST430, and a homozygous exon 11 missense mutation (V560D) and a heterozygous secondary exon 17 mutation (D820A) exist for GIST48 cells.

KEYWORDS

Aurora kinase A, BPR1J373, gastrointestinal stromal tumor, KIT, multitargeted kinase inhibitor
GIST62, GIST48B, and COS-1 cells were confirmed to be KIT-null by RT-PCR in January 2017 and March 2016. In July 2018, GIST-T1 was confirmed by direct sequencing to contain an exon 11 (V560-Y579) deletion. BPR1J373 was supplied by Dr. Weir-Torn Jiaang (Institute of Biotechnology and Pharmaceutical Research, NHRI). Sunitinib, imatinib, nilotinib, and regorafenib were purchased from Selleckchem (Houston, TX, USA).

2.2 | Apoptosis assay

Gastrointestinal stromal tumor cell lines GIST882, GIST430, and GIST48 were cultured in 6-well plates and treated with or without 2x IC_{50} and 1 μmol/L BPR1J373. The cells were collected at prespecified times, stained with annexin V-phycoerythrin and propidium iodide, and analyzed by BD FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA).

2.3 | Cell proliferation assay

Gastrointestinal stromal tumor cells (4 × 10^4) were treated with different dosages of BPR1J373. The treated GIST882 cells were incubated for 144 h, and GIST48, GIST430, and GIST-T1 cells were incubated for 120 hours at 37°C in 5% CO_2. Cell proliferation was determined by incubating the cells with methylene blue (Clontech, Mountain View, CA, USA) for 1 hour. The absorbance was measured at 450 nm using the SpectraMax M5 microplate reader (Molecular Devices, San Jose, CA, USA).

2.4 | Western blot analysis

The GIST cells were treated with 1 μmol/L imatinib, sunitinib, nilotinib, regorafenib, and BPR1J373 at prespecified time points to evaluate the time effect. The GIST cells were treated with different doses of BPR1J373 for 24 hours to evaluate the dose effect. Cell lysates were extracted with CelLytic M mammalian cell lysis/extraction solution purchased from Sigma (St. Louis, MO, USA). The cell lysates were resolved in SDS-PAGE gel and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). Non-specific binding was blocked using 5% BSA/PBST for 1 h, and the gels were washed four times with 0.1% Tween-20/PBS, followed by incubation with primary antibodies overnight at 4°C. The immunocomplexes were detected by probing with anti-mouse or anti-rabbit IgG conjugated with HRP and visualized using an Enhanced Chemiluminescence detection kit (Western Lightning Plus-ECL; PerkinElmer, Waltham, MA, USA). The primary antibodies Pi3K, AKT, p-AKT, poly(ADP-ribose) polymerase (PARP), Puma, Bax, Bad, Bak, p21, Aurora A, p-Aurora A, Aurora B, p-Aurora ABC, p-Rb, p-MEK, and p-MAPK were purchased from Cell Signaling (Danvers, MA, USA). Antibodies against Bcl-2, BcL-xl, p53, p16, and GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, TX, USA). Antibody against p-KIT was purchased from Invitrogen (Frederick, MD, USA). P27 was purchased from BD Transduction Laboratories (BD Biosciences). KIT was purchased from Dako (Carpinteria, CA, USA).

2.5 | Cell cycle analysis

Cells were treated with or without BPR1J373, sunitinib, nilotinib, or regorafenib and harvested at the designed time courses. The harvested cells were washed twice with PBS and fixed overnight with 70% cold ethanol. The cells were collected by centrifugation at 5000 × g for 5 minutes, incubated with 0.2 mg/mL RNase A (Sigma) for 1 hour, and stained with 20 μg/mL propidium iodide (Sigma) at room temperature. The stained cells were measured using a FACSCalibur machine, and the data were analyzed with the WinMDI 2.9 software (Purdue University Cytometry Laboratories, West Lafayette, IN, USA). Data represent the mean ± SE of triplicate experiments.

2.6 | β-Galactosidase staining

Amounts of 3 × 10^5 GIST48 cells were cultured with or without 10 nmol/L, 100 nmol/L, or 1 μmol/L BPR1J373. The cells in each condition were harvested 96 hours later and washed twice with 1× PBS. The cells were transferred to a slide by cytospinning at 500 rpm for 5 minutes and fixed with 0.5% glutaraldehyde for 10 minutes at room temperature. The slides were washed twice with 1× PBS and stained with β-galactosidase solution (Invitrogen, Foster City, CA, USA) at 37°C in the dark overnight. The slides were washed twice with 1× PBS for further evaluation.

2.7 | KIT-mutant transfections

Plasmids containing KIT mutations were produced as described previously. COS-1 cells were cultured in a 6-cm plate overnight and added with vector (pcDNA3.1) only, or vector with WT or mutant KIT with Lipofectamine 2000 (11668-019; Invitrogen) according to the manufacturer’s protocol. The cells were cultured for 24 hours and treated with or without drugs (imatinib, sunitinib, nilotinib, regorafenib, and BPR1J373) for the indicated time. The cell lysates in each condition were collected for western blot analysis.

2.8 | Animal study

NOD-SCID male mice (6-8 weeks old) were obtained from the National Laboratory Animal Center (Tainan, Taiwan) and housed under specific pathogen-free conditions according to the guidelines of the Animal Care Committee at the NHRI. GIST430 cells (2 × 10^5/mouse) were injected s.c. into the mice. The mice were treated with a vehicle control, sunitinib 40 mg/kg, regorafenib 30 mg/kg, or BPR1J373 50 mg/kg from day 1 to day 5 with 2 days of rest for 2 weeks after tumor growth to 50–100 mm^3. The doses of sunitinib and regorafenib were chosen according to efficacy studies in mouse xenograft models. The maximum tolerated dose of BPR1J373 was 75 mg/kg, and we chose 50 mg/kg in this study for safety considerations. The drugs were dissolved in 20% (2-hydroxypropyl)β-cyclodextrin (Sigma) for oral feeding. The tumor volume was measured three times per week for up to 16 days using the following formula: length (mm) × width^2 (mm^2) × π/6. Body weight was also measured at the same time as the tumor measurement.
3 | RESULTS

3.1 | BPR1J373 inhibited the proliferation of KIT-mutant GIST cells

Gastrointestinal stromal tumor cell lines, including KIT-dependent GIST882, GIST48, and GIST430 and KIT-null GIST48B and GIST62, were treated with BPR1J373 and screened for the inhibitory effect of BPR1J373 on cell proliferation using methylene blue staining. The BPR1J373 IC50 values for 2x doubling time were 14.8, 3.9, 4.5, >2000, and >2000 nmol/L in GIST882, GIST430, GIST48, GIST62, and GIST48B cell lines, respectively. BPR1J373 did not suppress cell proliferation in the KIT-null GIST cell lines. Compared with imatinib, sunitinib, nilotinib, and regorafenib, the IC50 values of BPR1J373 that suppress cell proliferation in the three KIT-mutant GIST cell lines are much lower (Figure 1A). Among the drugs for comparison with

![Graphs showing survival rates and IC50 values for GIST cell lines treated with BPR1J373, imatinib, sunitinib, nilotinib, and regorafenib.](image)
BPR1J373, imatinib was relatively active against GIST882, sunitinib was active against GIST882 and GIST430, and nilotinib had the greatest activity against GIST48. Regorafenib was less effective than sunitinib and nilotinib in suppressing the growth of GIST430 and GIST48, respectively. Another imatinib-sensitive GIST cell line, GIST-T1, was also evaluated for an antiproliferative effect by the above agents. BPR1J373, sunitinib, and nilotinib exerted the best antiproliferative effects, as shown in Figure S2A.

3.2 | BPR1J373 effectively suppressed KIT phosphorylation and downstream signaling in GIST cell lines

Because KIT is a driving oncogene responsible for the cell growth of GIST cells with KIT mutations, activation of KIT was determined by its phosphorylation status in GIST882, GIST430, and GIST48 cells. Western blot analysis revealed that phosphorylation of KIT in the KIT-mutated GIST cells was dramatically decreased by 100 nmol/L BPR1J373 within 2 hours (Figure 1B). BPR1J373 exerted the most potent effect on inhibiting KIT activation and the downstream signals of KIT in GIST882 cells; this effect was better than those of imatinib, sunitinib, nilotinib, and regorafenib (Figure 1C). The potency of KIT inhibition in GIST430 and GIST48 was observed in the treatment with sunitinib and nilotinib, respectively. In contrast, BPR1J373 displayed no differential potency among these cells and remarkably downregulated KIT activation and its driven signaling molecules such as AKT, MEK, and MAPK (Figure 1C). Furthermore, BPR1J373, as well as imatinib, sunitinib, nilotinib, and regorafenib, exerted a potent effect in suppressing KIT activation and its downstream signaling molecules of imatinib-sensitive GIST-T1 cells (Figure S2B,C).

3.3 | BPR1J373 differentially induced cell apoptosis of KIT-mutated GIST cells

To investigate the mechanisms of the inhibitory effect of BPR1J373 on GIST cells, we evaluated the molecular markers of apoptosis. Cleavage of PARP was evident in the three KIT-dependent GIST cell lines after 48 hours of exposure to BPR1J373 (Figure 2A). We further evaluated the effect of BPR1J373 on mitochondria-associated apparatuses that regulate cell survival and apoptosis. BPR1J373 had a profound effect on the upregulation of pro-apoptotic molecules Bax and Puma in GIST48 and GIST430 cells. BPR1J373 also induced the upregulation of Bax and Bak in GIST882 cells. No change in pro-survival molecules Bcl2 and BcL-xL was noted for GIST430 cells, whereas BPR1J373 significantly suppressed the expression of Bcl2 in GIST48 cells, as shown in

![Figure 2](image-url)
Figure 2B. The expression of Bcl2 in GIST882 was suppressed by BPR1J373. Furthermore, the apoptotic effect of BPR1J373 in GIST cells was also determined by annexin-V/propidium iodide staining. The annexin-V-positive cells increased gradually in response to increased exposure time of GIST882, GIST48, and GIST430 to BPR1J373 at a concentration of 1 μmol/L (Figure 2C). More than 70% of GIST882 cells

Figure 3. BPR1J373 induced cell cycle arrest in gastrointestinal stromal tumor (GIST)430 and GIST48 cells. A, Cell cycle analysis for GIST430 cells treated with indicated doses of BPR1J373 over time. B, Cell cycle analysis for GIST48 cells treated with BPR1J373 in indicated doses over time. C, Cell cycle analysis of GIST430 cells treated with indicated doses of sunitinib and imatinib over time. D, Cell cycle analysis of GIST48 cells treated with indicated doses of nilotinib and imatinib over time.

Figure 4. BPR1J373 induced senescent change of gastrointestinal stromal tumor (GIST)48 cells by targeting of Aurora kinase A. A, β-Galactosidase staining of GIST48 cells treated with the indicated dose of BPR1J373 for 96 hours. B, Protein expression of total and phosphorylated (p-) forms of Aurora A and B, and the cell cycle-associated proteins in GIST48 cells treated with or without 1 μmol/L BPR1J373 for indicated durations.
were annexin-V-positive after 96 hours of exposure to BPR1J373. The cells were treated with their corresponding double IC50 doses (2 × IC50) of BPR1J373. Intriguingly, the apoptotic event for GIST882 cells obviously remained in a time-dependent manner but was less significant for GIST48 and GIST430 cells (Figure 2D). This result indicates that BPR1J373 inhibited cell proliferation of GIST882 cells mainly through

**FIGURE 5** BPR1J373 suppressed KIT phosphorylation of KIT-mutant transfected COS-1 gastrointestinal stromal tumor cells. A, Inhibitory effect of 1 μmol/L of the 5 tyrosine kinase inhibitors (TKIs) on phosphorylation of KIT in COS-1 cells transfected with KIT single mutation plasmids. B, Inhibitory effect of the 5 TKIs on phosphorylation of KIT in COS-1 cells transfected with KIT double mutation plasmids.

**FIGURE 6** BPR1J373 suppresses tumor growth of GIST430 xenograft. A, Tumor growth curves and pictures of tumors of GIST430 xenograft mice treated with vehicle control, sunitinib, regorafenib, and BPR1J373. *Control vs sunitinib, P = 0.03 (Wilcoxon rank sum test); **Control vs BPR1J373, P = 0.02 (Wilcoxon rank sum test). B, KIT and phosphorylated (p-)KIT expression of tumors in GIST430 xenograft mice treated with vehicle control, sunitinib, regorafenib, or BPR1J373.
induction of apoptosis. However, the percentage of annexin-V-positive cells was much lower than the inhibitory proportion of BPR1J373-treated GIST48 and GIST430 cells (Figure 1A). This result suggests that antiproliferation of GIST48 and GIST430 by BPR1J373 might be mediated by both apoptotic- and non-apoptotic-dependent mechanisms.

3.4 | Cell cycle arrest and cellular senescence caused by BPR1J373

To investigate the potential non-apoptotic events in GIST48 and GIST430 cells, the cell cycle was further analyzed after BPR1J373 treatment at the indicated dose and time points. Compared with the control, a decrease in S phase and increase in G2/M phase were noted in GIST430 cells after exposure to 10 nmol/L, 100 nmol/L, and 1 μmol/L BPR1J373, as shown in Figure 3A. For GIST48 cells, treatment with 10 nmol/L and 100 nmol/L BPR1J373 apparently caused a decrease in both S and G2/M phases but gradually increased the sub-G1 or G2/G phase. Intriguingly, 1 μmol/L BPR1J373 caused a marked decrease in G2/G phase but simultaneously increased the S and G2/M cell populations in a time-dependent manner (Figure 3B). The results in Figure 3C show that alteration of the cell-cycle subpopulations induced by imatinib or sunitinib displayed a similar pattern comparable to that caused by 10 nmol/L and 100 nmol/L BPR1J373 for GIST430 cells. Neither 1 μmol/L imatinib nor nilotinib induced S or G2/M arrest in GIST48 cells, but 1 μmol/L BPR1J373 did (Figure 3D). Regorafenib did not induce significant cell cycle changes in GIST430 cells and induced only a mild increase in subG1 and a mild decrease in S and G2/M proportions of GIST48 cells (Figure S3).

Because cell cycle arrest at the G2/M phase of GIST430 and GIST48 cells was noted with BPR1J373 treatment, we undertook β-galactosidase staining to evaluate whether senescent change was induced by BPR1J373. Figure 4A shows increased numbers and density of β-galactosidase-positive GIST48 cells after treatment with 10 nmol/L, 100 nmol/L, and 1 μmol/L BPR1J373 for 96 hours, whereas these responses were not convincingly observed in GIST430 cells. Uptregulation of senescence-associated genes, including HPIγ, p19, p53, and HMGA1, further supported the induction of senescent formation in GIST48 cells treated with BPR1J373, particularly at a dose of 1 μmol/L (Figure S4). Hypophosphorylation of Rb protein and increased expression of p21 and p27 were found in GIST48 treated with BPR1J373 (Figure 4B). In addition, because BPR1J373 was shown to have an inhibitory effect on the activation of Aurora kinase, we examined the expression of Aurora kinase A and B and found that the phosphorylation of Aurora kinase A could be suppressed by BPR1J373 in GIST48 cells (Figure 4B). Thus, data suggest that BPR1J373-induced senescence in GIST48 cells might be mediated by the inactivation of Aurora kinase A activity.

3.5 | BPR1J373 suppressed KIT activation of COS-1 cells with KIT-mutant genes

To determine whether BPR1J373 suppresses KIT phosphorylation for other KIT mutations common in GIST, we transfected COS-1 cells using plasmids with various KIT mutant genes, including single (AY502-503 duplication in exon 9, Δ557-558 deletion in exon 11, V560D in exon 11, V654A in exon 13, T670I in exon 14, and D820G, N822K, and D816V in exon 17) and double mutations (Δ557-558 in exon 11/V654A in exon 13, Δ557-558 in exon 11/T670I in exon 14, Δ557-558 in exon 11/D820G in exon 17, and Δ557-558 in exon 11/N822K in exon 17). COS-1 cells transfected with the KIT mutants were treated with 1 μmol/L BPR1J373, imatinib, sunitinib, nilotinib, or regorafenib for 30 minutes. All 5 drugs were able to suppress KIT phosphorylation of COS-1 cells with individual single mutations in exons 9 and 11 with BPR1J373 as the most potent. Imatinib, sunitinib, nilotinib, and regorafenib differentially suppressed KIT phosphorylation in COS-1 cells with single mutations in exons 13, 14, and 17. Compared with the 4 drugs, BPR1J373 exerted the most potent effect on suppression of KIT phosphorylation of these COS-1 transfectants, as shown in Figure 5A. Furthermore, BPR1J373 also showed a remarkable potency in the suppression of KIT activation in COS-1 transfectants with all 4 double mutations, whereas imatinib, sunitinib, nilotinib, and regorafenib showed variable effects on suppression of KIT phosphorylation (Figure 5B). For D816V in exon 17, which is resistant to imatinib, sunitinib, and nilotinib, BPR1J373 still suppressed KIT phosphorylation in a time-dependent manner, whereas the other 3 tyrosine kinase inhibitors did not, as shown previously.26

3.6 | Tumor growth suppressed by BPR1J373 in a xenograft model

To test the therapeutic effect of BPR1J373 in vivo, GIST430 cells were s.c. grafted into NOD-SCID mice. After tumor inoculation, the mice were orally treated with BPR1J373 (50 mg/kg), sunitinib (40 mg/kg), regorafenib (30 mg/kg), or vehicle control from day 1 to day 5 per week for 2 consecutive weeks. The body weight and tumor volume of each mouse were measured daily after the animals were killed after completion of treatment. There were 5 mice in the control group and 6 mice each in the BPR1J373, sunitinib, and regorafenib groups. All mice were alive before the completion of the experiment except for 1 mouse in the regorafenib group that died at day 14. BPR1J373 at the designed dose caused a mild body weight loss compared with control mice (mean ± SE, 30.74 ± 0.34 g). Body weights were not significantly different among mice treated with the 3 drugs (28.82 ± 0.52 g in the regorafenib group; 29.1 ± 1.04 g in the sunitinib group; 27.8 ± 0.30 g in the BPR1J373 group). The body weight changes of the mice in the treatment period are shown in Figure 55. Although these 3 drugs could suppress the tumor growth compared with the control, only sunitinib (P = 0.03, Wilcoxon rank sum test) and BPR1J373 (P = 0.02, Wilcoxon rank sum test) showed statistically significant antitumor effects. The antitumor effect of BPR1J373 was greater than that of regorafenib, although not statistically significant (P = 0.15, Wilcoxon rank sum test). The tumor sizes of mice in the BPR1J373 and sunitinib groups were comparable (P = 0.59, Wilcoxon rank sum test; Figure 6A). In addition, decreased
expression levels of KIT and KIT phosphorylation were observed in mice treated with BPR1J373, sunitinib, or regorafenib compared with those in the controls (Figure 6B). Taken together, all data indicated that BPR1J373 was more effective in suppressing tumor growth of GIST430 cells and showed a non-inferior effect compared with sunitinib in vivo.

Collectively, these studies indicate that BPR1J373 induced cell apoptosis or cell cycle arrest/senescence in KIT-mutated GIST cells by targeting KIT and likely Aurora kinase A. The antiproliferative effect shown in tumor-grafted mice suggests that BPR1J373 could be a potential anticancer drug for GIST, therefore, further investigation for its clinical applications is warranted.

4 | DISCUSSION

KIT is the major target for current GIST treatments. Imatinib targets KIT and its downstream signals, thereby inhibiting GIST cell proliferation and inducing apoptosis. Resistance to imatinib is an inevitable consequence of most advanced GIST patients, and the mechanisms of resistance to imatinib have been widely studied. KIT mutations (including primary and secondary mutations), drug metabolism, gene amplification of KIT or PDGFRα, activation of alternate growth pathways, and loss of KIT can all contribute to resistance to imatinib. The differential inhibitory effect on KIT phosphorylation of commercially available TKIs, including imatinib, sunitinib, nilotinib, dasatinib, and sorafenib, was evident in the in vitro KIT-expressing COS-1 cell-based system. No single drug showed a potent effect targeting all of the common KIT mutations in GIST, including single and double mutations. This result corresponds to the variable responses to these TKIs among advanced GIST patients. In the present study, we revealed the potent antiproliferative effect of BPR1J373 in suppressing the growth of both imatinib-sensitive and imatinib-resistant GIST cell lines. Furthermore, the inhibition of KIT phosphorylation by BPR1J373 in a COS-1 cell-based system was superior to that obtained with other available TKIs for various KIT mutations, including KIT D816V mutation, which is resistant to all available TKIs. In addition to KIT, other targets were shown to contribute to the survival of GIST. Sunitinib was shown to be effective for GIST by targeting KIT and VEGFR. In an in vitro study, sorafenib was shown to be a potential active agent for GIST based on its potent suppression of mutant KIT and PDGFRα. Abrogation of the protective effect of heat shock protein 90 in preventing KIT proteasome-mediated degradation is another approach for targeting imatinib-resistant KIT-positive GIST and has been evaluated in clinical trials. Monoclonal antibodies targeting PDGFRα and VEGFR, mTOR inhibitors, and PI3K/AKT inhibitors have also been studied to treat GIST in phase II or III studies in patients with imatinib-resistant GIST. The efficacy of these agents remains to be determined.

In our study, BPR1J373 induced apoptosis in imatinib-sensitive and imatinib-resistant GIST cells via targeting KIT. Moreover, compared with sunitinib, nilotinib, and regorafenib, BPR1J373 exerted a more potent inhibitory effect on KIT phosphorylation and its downstream signals AKT and MEK in GIST882, GIST48 and GIST430 cells. For imatinib-resistant GIST430 and GIST48 cells, the antiproliferative effect of BPR1J373 is thought to occur through targeting of KIT-induced apoptosis and other mechanisms. BPR1J373 induced up to 30% and 50% of apoptotic cells in GIST430 and GIST48 cells, respectively, as shown in Figure 2. However, the survived GIST430 and GIST48 cells after BPR1J373 treatment were only approximately 20% of the untreated cells, as shown in Figure 1. Therefore, the antiproliferative effect of GIST430 and GIST48 by BPR1J373 is suspected to be caused by the synergistic effect of apoptosis and cell cycle arrest, as shown in Figures 2 and 3.

In this study, we found that BPR1J373 evoked senescence and G2/M arrest in imatinib-resistant GIST48 cells. BPR1J373 also induced G2/M arrest in GIST430 cells. Yeh et al showed that overexpression of Aurora kinase A has been associated with poor overall survival in GIST patients, and MLN8273, an Aurora kinase A inhibitor, was shown to induce apoptosis, G2/M arrest and senescence in imatinib-resistant GIST cell lines. In our study, BPR1J373 induced cell cycle arrest and senescent change in GIST48 cells, which is consistent with the result reported by Yeh et al with Aurora kinase A inhibitor MLN8273. In addition, the inhibitory effect on Aurora kinase A in GIST48 cells by BPR1J373 further supports the hypothesis that the antiproliferative effect of BPR1J373 in GIST48 cells occurs through targeting of KIT and Aurora kinase A. This result also suggests that the cell growth of GIST48 is dependent on Aurora kinase A activity. The antiproliferative effect of BPR1J373 in imatinib-sensitive GIST882 cells occurs mainly through induction of apoptosis because BPR1J373 induced more than 70% of annexin-V-positive GIST882 cells, either in low or high dose, as shown in Figure 2C-D. BPR1J373 also exerted an inhibitory effect on Aurora kinase A and B in GIST882 cells, as shown in Figure S6, which suggests that the induction of apoptosis in GIST882 might occur through targeting of KIT and possibly Aurora kinase A and B. We have previously shown that BPR1J373 was effective in suppressing phosphorylation of Aurora kinase B and inducing polyplody of the acute myeloid leukemia cell line KG-1. Although BPR1J373 has both anti-Aurora kinase A and B activity, its inhibition on Aurora kinase A or B might depend on the cellular contents of different cancer cell types.

In conclusion, BPR1J373, a multitargeted TKI, effectively inhibits the proliferation of KIT-mutant GIST cells by inducing cell apoptosis and cell cycle arrest/senescence by targeting KIT and Aurora kinase A. Compared with other TKIs, BPR1J373 exerts a more potent inhibitory effect on KIT. The antitumor effect of BPR1J373 was also evident in a GIST430 xenograft mouse model. Therefore, BPR1J373 is a potential anticancer drug for advanced GIST and deserves further investigation for clinical use.

ACKNOWLEDGEMENTS

We acknowledge the funding support by the National Health Research Institutes (CA104-PP-18, and CA-105-PP-18) and Ministry of Science Technology (104-2325-B-400-003, 105-2325-B-400-002, and 103-2314-B-400-013).
CONFLICT OF INTEREST
The authors have no conflict of interest.

ORCID
Hui-Jen Tsai http://orcid.org/0000-0001-5246-5748

REFERENCES
1. Joensuu H, Hohenberger P, Corless C. Gastrointestinal stromal tumour. Lancet. 2013;382:973-983.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
4. Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
7. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic response to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
8. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologische and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2005;99:1928-1937.
9. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
10. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour. N Engl J Med. 2001;344:1052-1056.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
12. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phased trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620-625.
13. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase:50033. J Clin Oncol. 2008;26:626-632.
14. Gouder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011;67(Suppl 1):S25-543.
15. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865-878.
16. Debiec-Rychter M, Sciut R, Les Cse A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093-1103.
17. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for treatment of advanced gastrointestinal stromal tumor: GALGB 150105 study by cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360-5367.
18. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with Imatinib Mesylate. Clin Cancer Res. 2006;12:1743-1749.
19. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
20. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol. 2010;28:1247-1253.
21. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182-4190.
22. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64-74.
23. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352-5359.
24. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
25. Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of sunitinib in gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
26. Chen LT, Chen CT, Jiaang WT, et al. Selecting tyrosine kinase inhibitors: targets for the treatment of c-kit-driven myeloid leukemia. Mol Cancer Ther. 2016;15:2323-2333.
27. Hsueh YS, Yen CC, Shih NY, et al. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy. 2013;9:220-233.
28. Mendel DB, Laird AD, Xion X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
29. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011-1021.
30. Guérin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol. 2008;134:51-57.
31. Bauerschlag DO, Schem C, Tiwari S, et al. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res. 2010;30:3355-3360.
32. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506) in gastrointestinal stromal tumours under treatment with Imatinib Mesylate. J Clin Oncol. 2008;26:5360-5367.
33. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA. 2006;103:57-62.
34. Hsueh YS, Lin CL, Chiang NJ, et al. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS ONE. 2013;8(6):e65762.
35. Heinrich MC, Marino-Enriquez A, Presnell A, et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. *Mol Cancer Ther.* 2012;11:1770-1780.

36. Bauer S, Duensing A, Demetri GD, et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. *Oncogene.* 2007;26:7560-7568.

37. Sápi Z, Füle T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. *Diagn Mol Pathol.* 2011;20:22-33.

38. Yeh CN, Yen CC, Chen YY, et al. Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. *Oncotarget.* 2014;5:4071-4086.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Tsai H-J, Jiaang W-T, Shih N-Y, et al. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. *Cancer Sci.* 2018;109:3591-3601. [https://doi.org/10.1111/cas.13773](https://doi.org/10.1111/cas.13773)